Low-molecular-weight estrogenic phytoprotein suppresses osteoporosis development through positive modulation of skeletal estrogen receptors.

John Akrofi Kubi, Augustine Suurinobah Brah, Kenneth Man Chee Cheung, Andy Chun Hang Chen, Yin Lau Lee, Kai-Fai Lee, Wei Qiao, Yibin Feng, Kelvin Wai Kwok Yeung

Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), PR China.Department of Orthopaedics and Traumatology, Li Ka Shing Faculty of Medicine, The University of Hong Kong (HKU), PR China. · pubmed

Paper

Abstract

Age-related osteoporosis is a metabolic skeletal disorder caused by estrogen deficiency in postmenopausal women. Prolonged use of anti-osteoporotic drugs such as bisphosphonates and FDA-approved anti-resorptive selective estrogen receptor modulators (SERMs) has been associated with various clinical drawbacks. We recently discovered a low-molecular-weight biocompatible and osteoanabolic phytoprotein, called HKUOT-S2 protein (32 kDa), from

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper addresses osteoporosis, a condition linked to aging, and explores a novel phytoprotein that may modulate estrogen receptors to suppress its development. While it presents a potential therapeutic approach, it primarily focuses on treatment rather than addressing the underlying causes of aging or longevity. Thus, its impact is solid but limited in the broader context of longevity research.

Author of this paper? Send a correction.